Japan Inc shows promise with savvy holiday deal spree
WHILE much attention has been focused on Japan's big ailing companies and their prospects for survival, a few small developments show some promising signs for the country's future.
Kicking off a week in deals, Asahi Glass Co said on Dec 20 it would buy CMC Biologics for 60 billion yen (S$739 million), helping its move into contract drug manufacturing.
While Asahi Glass gets half its sales from glass used in buildings and cars, the electronics sector provides over 40 per cent of its operating profit. Yet even that division is overshadowed by the chemicals business, which includes solvents, pharmaceutical ingredients and resins, and which has grown to account for 43 per cent of earnings.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Columns
‘Competition for talent’ a poor excuse to keep key executives’ pay under wraps
OCBC should put its properties into a Reit and distribute the trust’s units to shareholders
Why a stronger US dollar is dangerous
An overstimulated US economy is asking for trouble
Too many property agents? Cap commissions on home sales
Time to study broadening of private market access